Gland Pharma Limited (NSE:GLAND)

Gland Pharma Statistics

Total Valuation

Gland Pharma has a market cap or net worth of INR 278.39 billion. The enterprise value is 251.03 billion.

Market Cap	278.39B
Enterprise Value	251.03B

Important Dates

The last earnings date was Tuesday, May 20, 2025.

Earnings Date	May 20, 2025
Ex-Dividend Date	Aug 14, 2025

Share Statistics

Gland Pharma has 164.76 million shares outstanding. The number of shares has increased by 0.01% in one year.

Current Share Class	164.76M
Shares Outstanding	164.76M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	37.36%
Float	73.18M

Valuation Ratios

The trailing PE ratio is 39.85 and the forward PE ratio is 29.56. Gland Pharma's PEG ratio is 1.37.

PE Ratio	39.85
Forward PE	29.56
PS Ratio	4.96
PB Ratio	3.04
P/TBV Ratio	3.16
P/FCF Ratio	52.51
P/OCF Ratio	30.43
PEG Ratio	1.37

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.78, with an EV/FCF ratio of 47.35.

EV / Earnings	35.94
EV / Sales	4.47
EV / EBITDA	19.78
EV / EBIT	28.17
EV / FCF	47.35

Financial Position

The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.03.

Current Ratio	4.33
Quick Ratio	2.92
Debt / Equity	0.03
Debt / EBITDA	0.25
Debt / FCF	0.59
Interest Coverage	21.22

Financial Efficiency

Return on equity (ROE) is 7.82% and return on invested capital (ROIC) is 6.00%.

Return on Equity (ROE)	7.82%
Return on Assets (ROA)	5.09%
Return on Invested Capital (ROIC)	6.00%
Return on Capital Employed (ROCE)	9.22%
Revenue Per Employee	13.10M
Profits Per Employee	1.63M
Employee Count	4,286
Asset Turnover	0.51
Inventory Turnover	1.36

Taxes

In the past 12 months, Gland Pharma has paid 3.64 billion in taxes.

Income Tax	3.64B
Effective Tax Rate	34.27%

Stock Price Statistics

The stock price has decreased by -9.82% in the last 52 weeks. The beta is 0.32, so Gland Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.32
52-Week Price Change	-9.82%
50-Day Moving Average	1,503.42
200-Day Moving Average	1,651.81
Relative Strength Index (RSI)	74.87
Average Volume (20 Days)	168,749

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Gland Pharma had revenue of INR 56.17 billion and earned 6.99 billion in profits. Earnings per share was 42.40.

Revenue	56.17B
Gross Profit	33.27B
Operating Income	8.91B
Pretax Income	10.63B
Net Income	6.99B
EBITDA	12.69B
EBIT	8.91B
Earnings Per Share (EPS)	42.40

Balance Sheet

The company has 30.50 billion in cash and 3.14 billion in debt, giving a net cash position of 27.36 billion or 166.07 per share.

Cash & Cash Equivalents	30.50B
Total Debt	3.14B
Net Cash	27.36B
Net Cash Per Share	166.07
Equity (Book Value)	91.51B
Book Value Per Share	555.30
Working Capital	52.18B

Cash Flow

In the last 12 months, operating cash flow was 9.15 billion and capital expenditures -3.85 billion, giving a free cash flow of 5.30 billion.

Operating Cash Flow	9.15B
Capital Expenditures	-3.85B
Free Cash Flow	5.30B
FCF Per Share	32.18

Margins

Gross margin is 59.24%, with operating and profit margins of 15.86% and 12.44%.

Gross Margin	59.24%
Operating Margin	15.86%
Pretax Margin	18.92%
Profit Margin	12.44%
EBITDA Margin	22.59%
EBIT Margin	15.86%
FCF Margin	9.44%

Dividends & Yields

This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 1.07%.

Dividend Per Share	18.00
Dividend Yield	1.07%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	47.17%
Buyback Yield	-0.01%
Shareholder Yield	1.06%
Earnings Yield	2.51%
FCF Yield	1.90%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7